By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Someone right this moment has just chosen to start a biopharma company. How will it happen?
Most likely, the startup will embark on the standard pathway from angel and seed money, perhaps all the way to an IPO. Startups rarely make profits, but they typically attract investment on the hope they will become profitable someday and produce positive returns for their investors along the way. But what if the founder could take another, at least additional, route? What if, for certain ambitious, but traditionally underfunded, areas needing innovation, the enterprise could achieve its ends without the usual for-profit incentives?